Genetron Health to Announce Second Quarter Unaudited Financial Results and Host Investor Call on August 6, 2020
Genetron Holdings Limited (NASDAQ:GTH) announced it will release its second quarter financial results for the period ending June 30, 2020, on August 6, 2020, before the US market opens. A conference call for investors will follow at 8:30 a.m. ET, providing details on the Company's performance in precision oncology and molecular profiling tests. The Company leverages advanced technologies in molecular biology and data science for cancer management. Interested parties can access the call and its replay via specified numbers and the Company’s investor relations website.
- Upcoming conference call to discuss financial results may provide insights into growth in precision oncology.
- Genetron's focus on advanced cancer management technologies positions it favorably in the oncology market.
- None.
BEIJING, July 27, 2020 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ:GTH), a leading precision oncology company in China that specializes in offering molecular profiling tests, today announced that it will report unaudited financial results for the second quarter ended June 30, 2020, on August 6, 2020, before the US market open.
Management will host a conference call for investors at 8:30 a.m. ET (8:30 p.m. Beijing time) on Thursday, August 6, 2020. The conference call can be accessed by dialing the following numbers:
| United States: | +1 845-675-0437 |
| China Domestic: | 400-620-8038 |
| Hong Kong: | +852-3018-6771 |
| International: | +65-6713-5090 |
| Conference ID: | 1969177 |
Participants are encouraged to dial into the call at least 15 minutes in advance due to high call volumes.
A replay will be accessible through September 6, 2020, by dialing the following numbers:
| United States: | +1-646-254-3697 |
| International: | +61-2-8199-0299 |
| Conference ID: | 1969177 |
A simultaneous webcast of the conference call will be available on the "News and Events" page of the Investors section of the Company's website. A replay of the webcast will be available for 30 days following the event. For more information, please visit ir.genetronhealth.com.
About Genetron Holdings Limited
Genetron Holdings Limited (“Genetron Health” or the “Company”) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive oncology portfolio that covers the entire spectrum of cancer management, addressing needs and challenges from early screening, diagnosis and treatment recommendations, as well as continuous disease monitoring and care. Genetron also partners with global biopharmaceutical companies and offers customized services and products. For more information, please visit ir.genetronhealth.com.
Safe Harbor Statement
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as “may”, “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.
Investor Relations Contacts
US:
Hoki Luk
Head of Investor Relations
Email: hoki.luk@genetronhealth.com
Phone: +1 (408) 204-5343
Stephanie Carrington
Westwicke, an ICR Company
Email: Stephanie.Carrington@westwicke.com
Phone: +1 (646) 277-1282
Asia:
Bill Zima
ICR, Inc.
Email: bill.zima@icrinc.com
GenetronIR@icrinc.com
Media Relations Contact
Edmond Lococo
ICR
Edmond.Lococo@icrinc.com
Mobile: +86 138-1079-1408
genetron.pr@icrinc.com
FAQ
When will Genetron Holdings report its second quarter financial results?
What is the focus of Genetron Holdings?
How can I participate in the Genetron Holdings conference call?
What time is the Genetron Holdings conference call?
How long will the replay of the conference call be available?
